Related Experiment Video
Updated: Sep 17, 2025
Isolation and Identification of Extravascular Immune Cells of the Heart
Published on: August 23, 2018
Post-COVID Versus Non-COVID Myocarditis: Comparison of Morphological Activity, Toll-like Receptor Distribution and
Olga V Blagova1, Evgenia A Kogan2, Vladimir M Novosadov1
1Department of Faculty Therapy №1, N.V. Sklifosovsky Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University (Sechenov University), 119992 Moscow, Russia.
Insights
Post-COVID myocarditis exhibits distinct morphological features and heightened activity, with increased Toll-like receptor expression and a superior response to immunosuppressive therapy compared to non-COVID myocarditis.
Area of Science:
- Cardiology
- Immunology
- Pathology
Background:
- Direct clinical and morphological comparisons between non-COVID and post-COVID myocarditis are lacking.
- Understanding these differences is crucial for effective treatment strategies.
Purpose of the Study:
- To compare morphological activity, Toll-like receptor (TLR) distribution, and response to immunosuppressive therapy in non-COVID and post-COVID myocarditis patients.
- To elucidate distinct characteristics of myocarditis associated with severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) infection.
Main Methods:
- Analysis of 77 patients with biopsy-proven myocarditis and heart failure (ejection fraction <45%).
- Endomyocardial biopsies assessed via histology, PCR for viruses (including SARS-CoV-2), and immunohistochemistry for immune markers and TLRs.
- Patients received immunosuppressive therapy (steroids, azathioprine, mycophenolate mofetil).
Main Results:
- Post-COVID myocarditis showed varied morphological types (including eosinophilic), higher inflammatory cell infiltration (CD3, CD45), and increased TLR-4 and TLR-9 expression compared to non-COVID myocarditis.
- Despite similar baseline characteristics, post-COVID myocarditis patients demonstrated a significantly better response to immunosuppressive therapy, with a greater increase in ejection fraction.
- No significant differences were observed in age, heart failure severity, C-reactive protein, anti-heart antibodies, or mortality/transplantation rates.
Conclusions:
- Post-COVID myocarditis presents with unique morphological characteristics and heightened inflammatory activity.
- Increased Toll-like receptor expression may contribute to disease pathogenesis and treatment response.
- Post-COVID myocarditis appears to have a more favorable response to current immunosuppressive regimens.
Background:
A prior direct clinical and morphological comparison between non-coronavirus disease (COVID) myocarditis diagnosed before the severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) pandemic and post-COVID myocarditis has not been performed.
Purpose:
To compare morphological activity, Toll-like receptor distribution, and response to immunosuppressive therapy in patients with non-COVID and post-COVID myocarditis.
Methods:
In total, 77 patients (52 male and 25 female, 48.7 ± 11.7 years old) with biopsy-proven myocarditis, New York Heart Association (NYHA) class 2 or higher heart failure diagnoses, and an ejection fraction (EF) <45% were included. The exclusion criteria comprised a history of myocardial infarction, verified cardiomyopathies, systemic autoimmune diseases, and viral DNA in the myocardium, except parvovirus B19. A right ventricular endomyocardial biopsy was performed using hematoxylin and eosin and Van Gieson staining assays, alongside the polymerase chain reaction (PCR) for viruses (herpes viruses, parvovirus B19, adeno-, enteroviruses, and SARS-CoV-2). Moreover, immunohistochemical assays were conducted for CD3, CD45, CD68, CD20, nucleocapsid/spike proteins of SARS-CoV-2, and the subcellular distribution of Toll-like receptors (TLRs) type 4 and 9 (in 38 patients). The steroids (methylprednisolone 24-40 mg per day), azathioprine, and mycophenolate mofetil were prescribed. This study was observational and non-interventional. The mean follow-up was 15.0 [6.0; 35.5] months.
Results:
Myocarditis was diagnosed in 45 patients before the SARS-CoV-2 pandemic (giant cell in one case and lymphocytic in the others). Another 32 patients had post-COVID myocarditis that was positive for RNA or/and proteins of SARS-CoV-2 (giant cell in one case, eosinophilic in three cases, and lymphocytic in the others). There were no differences in age, NYHA classification, C-reactive protein (CRP) and anti-heart antibodies levels, echocardiographic parameters (mean EF: 30.2 ± 7.8 vs. 28.7 ± 6.7%), parvovirus B19 positivity (22 vs. 34%), methylprednisolone dosages (24-40 mg/day), and death/transplantation rate (11.1 vs. 9.4%). Differences between non-COVID and post-COVID myocarditis focused on higher CD3, CD 45*, and toll-like receptors (TLR)-4 (4+ vs. 6+) and TLR-9 (0 vs. 2+) levels, alongside subcellular distribution and a better response to therapy ((10% or more increase in EF in 53 vs. 86%* of patients, mean EF (43.9 ± 12.3 vs. 49.8 ± 7.6%*) by the end of follow-up); *p < 0.05).
Conclusion:
Post-COVID myocarditis is characterized by different morphological types, higher morphological activity, the tendency to increase TLR expression, and an improved response to immunosuppressive therapy compared to non-COVID myocarditis.
More Related Videos
12:24Noninvasive Assessment of Cardiac Abnormalities in Experimental Autoimmune Myocarditis by Magnetic Resonance Microscopy Imaging in the Mouse
Published on: June 20, 2014
08:13In Vivo Quantitative Assessment of Myocardial Structure, Function, Perfusion and Viability Using Cardiac Micro-computed Tomography
Published on: February 16, 2016
Related Concept Videos
01:27Myocarditis II: Clinical Features and Diagnostic Tests
01:21Myocarditis I: Introduction
01:14Myocarditis III: Medical Management
01:22Myocarditis IV: Nursing Management
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
01:19Pericarditis II: Clinical Features and Diagnostic Tests